At a glance
ClinicalIndex Comparison RecordN/ACompleted· 60 enrolled
Drug / intervention
zoledronic acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy
In Brief
A clinical study evaluating zoledronic acid and Letrozole as adjuvant therapy for Breast Cancer and Osteoporosis. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
RATIONALE: Zoledronate may reduce bone loss in patients receiving letrozole for breast cancer. PURPOSE: This clinical trial is studying how well zoledronate works in treating osteopenia or osteoporosis in postmenopausal women receiving letrozole for stage I, stage II, or stage IIIA primary breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Osteoporosis
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedFeb 2007
Primary CompletionJun 2008
Study CompletionMay 2016
TodayJul 2026
First PostedFeb 19, 2007
Enrollment StartApr 1, 2006
Primary CompletionJun 1, 2008
Study CompletionMay 9, 2016
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.4 years ago
Interventions
zoledronic aciddrug
zoledronic acid
Letrozole as adjuvant therapyprocedure
standard care